Avelumab in paediatric patients with refractory or relapsed solid tumours: dose-escalation results from an open-label, single-arm, phase 1/2 trial

BACKGROUND: We report dose-escalation results from an open-label, phase 1/2 trial evaluating avelumab (anti-PD-L1) in paediatric patients with refractory/relapsed solid tumours. METHODS: In phase 1, patients aged < 18 years with solid (including central nervous system [CNS]) tumours for which sta...

Descripción completa

Detalles Bibliográficos
Autores principales: Loeb, David M., Lee, Ji Won, Morgenstern, Daniel A., Samson, Yvan, Uyttebroeck, Anne, Lyu, Chuhl Joo, Van Damme, An, Nysom, Karsten, Macy, Margaret E., Zorzi, Alexandra P., Xiong, Julia, Pollert, Petra, Joerg, Ingrid, Vugmeyster, Yulia, Ruisi, Mary, Kang, Hyoung Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9463244/
https://www.ncbi.nlm.nih.gov/pubmed/35262780
http://dx.doi.org/10.1007/s00262-022-03159-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9463244/
https://www.ncbi.nlm.nih.gov/pubmed/35262780
http://dx.doi.org/10.1007/s00262-022-03159-8

Ejemplares similares